Eli Lilly is paying up to $630m for a Phase I MASH candidate from OliX Pharmaceuticals, diversifying its pipeline with an RNA ...

Shanghai-based brain-computer interface (BCI) company StairMed, which claims to outperform Elon Musk’s Neuralink in certain ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...

The stock's fall snapped a four-day winning streak.

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

We recently compiled a list of the 13 Best Dividend Growth Stocks With 10%+ Yearly Increases. In this article, we are going ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases.

Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a ...

An academic study of the merger hopes to give insight into how attorneys general can strengthen certificate-of-need laws and the importance of having more power over sales. Other industry news focuses ...